Presentation is loading. Please wait.

Presentation is loading. Please wait.

C-EDGE TN Study: grazoprevir/elbasvir in genotype 1, 4 or 6 Zeuzem S. Ann Intern Med 2015; 163:1-13 GZR/EBR 100/50 mg qd N = 316 N = 105  Design W12W24.

Published bySophia Cannon Modified over 8 years ago

Similar presentations

Presentation on theme: "C-EDGE TN Study: grazoprevir/elbasvir in genotype 1, 4 or 6 Zeuzem S. Ann Intern Med 2015; 163:1-13 GZR/EBR 100/50 mg qd N = 316 N = 105  Design W12W24."— Presentation transcript:

1 C-EDGE TN Study: grazoprevir/elbasvir in genotype 1, 4 or 6 Zeuzem S. Ann Intern Med 2015; 163:1-13 GZR/EBR 100/50 mg qd N = 316 N = 105  Design W12W24 W16 Placebo GZR/EBR W28 C-EDGE TN > 18 years HCV infection Genotype 1, 4, 6 Treatment-naïve HCV RNA > 10,000 IU/ml Compensated cirrhosis** allowed No HBV or HIV co-infection Randomisation* 3 : 1 Double blind * Randomisation was stratified on genotype (1 or 4 or 6) and cirrhosis (yes or no) ** Metavir F4 or fibroscan > 12.5 kPa or FibroTest > 0.75 + APRI > 2 Objective SVR 12 (HCV RNA < 15 IU/ml) by intention to treat analysis : superiority to historical SVR 12 of simeprevir + PEG-IFN + RBV (73%), at an overall 1-sided alpha value of 0.025, 99% power

2 GZR/EBR N = 316 Placebo N = 105 Age, years, mean52.253.8 Female46%47% Black / White / Asian 19% / 60% / 17%17% / 70% / 12% Genotype 1a 1b 4 6 50% 42% 6% 3% 51% 38% 8% 3% HCV RNA log 10 IU/ml6.4 IL28B CC34%35% Metavir F422%21% ALT, IU/L, mean (SD)77 (62)75 (64) Platelets < 10 9 /L, mean190194 Discontinuation, n For adverse event / lost to follow-up / death 5 3 / 1 / 1 1 1 / 0 / 0 C-EDGE TN Study: grazoprevir/elbasvir in genotype 1, 4 or 6 C-EDGE TN Baseline characteristics and patient disposition Zeuzem S. Ann Intern Med 2015; 163:1-13

3 C-EDGE TN C-EDGE TN Study: grazoprevir/elbasvir in genotype 1, 4 or 6 Non-virologic failure43100 Breakthrough11000 Relapse129102 100 75 50 25 0 94.6 (91.5-96.8) 92 (86-96) 99 (95-100) 100 (82-100) 80 (44-98) All patientsGenotype 1aGT 1bGT 4GT 6 3161571311810 % SVR 12 (HCV RNA < 15 IU/ml), % (95% CI) Zeuzem S. Ann Intern Med 2015; 163:1-13

4 C-EDGE TN C-EDGE TN Study: grazoprevir/elbasvir in genotype 1, 4 or 6 0 MaleCCNon-CCNoYes SVR 12 (HCV RNA < 15 IU/ml) by subgroup, % (95% CI) Female NoYes 100 75 50 25 93 (88-96) 93 (87-97) 96 (92-98) 94 (90-97) 97 (90-100) 17110620824670 % 145 94 97 (92-99) 100 (96-100) 92 (88-96) 222 Sex IL28B genotypeCirrhosis HCV RNA > 800 000 IU/ml Zeuzem S. Ann Intern Med 2015; 163:1-13

5 C-EDGE TN C-EDGE TN Study: grazoprevir/elbasvir in genotype 1, 4 or 6 RAV at baseline % (n/N) SVR 12 all patients % (N/n) SVR 12 RAVs with ≤ 5-fold  susceptibility SVR 12 RAVs with > 5-fold  susceptibility NS3 RAVs Genotype 1a Present Absent 57% (86/151) 43% (65/151) 97% (83/86) 89% (58/65) 97% (83/86) - 0% (0/0) - Genotype 1b Present Absent 19% (25/129) 81% (104/129) 96% (24/25) 100% (104/104) 96% (21/22) - 100% (3/3) - NS5A RAVs Genotype 1a Present Absent 12% (19/154) 88% (135/154) 58% (11/19) 99% (133/135) 90% (9/10) - 22% (2/9) - Genotype 1b Present Absent 14% (18/130) 86% (112/130) 94% (17/18) 100% (112/112) 100% (1/1) - 94% (16/17) - All 11 patients with virologic failure had baseline HCV RNA > 800,000 IU/ml (selection of NS5A RAV in 10/11) SVR 12 in genotype 1 according to baseline NS3 and NS5A RAVs Zeuzem S. Ann Intern Med 2015; 163:1-13

6 C-EDGE TN C-EDGE TN Study: grazoprevir/elbasvir in genotype 1, 4 or 6 NS3 RAVsNS5A RAVs GT Baseline HCV RNA (IU/ml) Day of virologic failure Baseline Emerging at failure (in addition) Baseline Emerging at failure (in addition) Breakthrough 1a1,238,923Rx D71Q80K, S122GV36ML31L/MQ30R Relapse 1a5,127,102F/U D28WTNoneL31MQ30R Relapse 1a2,134,448F/U D71WTD168AQ30H/QY93H Relapse 1a948,279F/U D70Q80KD168A M28V, Q30L, Y93H L31V Relapse 1a3,908,965F/U D84WTD168A M28M/V, H58H/D Q30R Relapse 1a5,282,871FU D62WTNoneL31MQ30R Relapse 1a1,846,427F/U D54WTNoneWTQ30R, L31M Relapse 1a1,939,436F/U D61WTY56H, D168AWTY93N Relapse 1b4,475,338F/U D89T54SV170IY93HL31F Relapse 1a3,913,374F/U D29V55AD168AQ30R, L31L/MNone Relapse 615,689,194F/U D25 V36I, L80Q, S122T, I132L, I170V D168YWTNone Relapse 1a1,574,151F/U D56WTNoneM28VM28G Relapse 615,056,901F/U D25L80K, I170VY56Y/H, D168EF28LL31M Baseline and emergent resistance variants in virologic failure cases Zeuzem S. Ann Intern Med 2015; 163:1-13

7 C-EDGE TN C-EDGE TN Study: grazoprevir/elbasvir in genotype 1, 4 or 6 Common AEs (> 5% in GZR/EBR) GZR/EBR N = 316 Placebo N = 105 Headache52 (17%)19 (18%) Fatigue49 (16%)18 (17%) Nausea28 (9%)8 (8%) Arthralgia20 (6%)6 (6%) Non-cirrhoticCirrhotic GZR/EBR N = 246 Placebo N = 83 GZR/EBR N = 70 Placebo N = 22 At least one adverse event175 (71%)57 (69%)38 (54%)15 (68%) Drug-related adverse event96 (39%)32 (39%)18 (26%)9 (41%) Serious adverse events7 (3%)3 (4%)2 (3%)0 (0%) Serious drug-related adverse event0 (0%) Discontinuation due to adverse event2 (1%)0 (0%)1 (1%)1 (5%) Death1 (<1%)0 (0%)1 (1%)0 (0%) Adverse events, n (%) Zeuzem S. Ann Intern Med 2015; 163:1-13

8 C-EDGE TN C-EDGE TN Study : grazoprevir/elbasvir in genotype 1, 4 or 6 GZR/EBR N = 316 Placebo N = 105 Late elevation of ALT or AST > 2.0-5.0 x ULN > 5.0 x ULN 3 (1.0%) 4 (1.3%) 4 (3.8%) 0 (0%) Elevation of total bilirubin > 2.5-5.0 x ULN > 5.0 x ULN 3 (0.9%) 1 (0.3%) 0 (0%) Decreased hemoglobin Grade 1-2 Grade 3-4 9 (2.9%) 0 (0%) 4 (3.8%) 0 (0%) Increased creatinine Grade 1 Grade 2 2 (0.6%) 0 (0%) 1 (1.0%) 0 (0%) Increased lipase Grade 1-2 Grade 3-4 101 (32.0%) 19 (6.0%) 25 (23.8%) 5 (4.8%) Laboratory abnormalities, n (%) Zeuzem S. Ann Intern Med 2015; 163:1-13

9 C-EDGE TN  Summary –A 12-week regimen of the oral fixed dose combination of once-daily, single-tablet of grazoprevir/elbasvir, achieved an overall SVR 12 of 95% High efficacy in genotypes 1 and 4 SVR 12 lower in genotype 6 High efficacy in cirrhotics (SVR 12 = 97.1%) Lower efficacy observed among patients with high viral load (HCV RNA > 800,000 IU/ml) –Overall virologic failure rate was 4% Baseline NS3 RAVS did not affect efficacy Association between virologic failure and the presence of baseline NS5A RAVs, which was most apparent in genotype 1a with baseline RAVs demonstrating > 5-fold potency reduction to elbasvir Emergence of (additional) NS3 and/or NS5A RAVs at failure was common –Grazoprevir/elbasvir was generally well-tolerated, with a similar safety profile in cirrhotic and non-cirrhotic patients –Limitations No active-control group C-EDGE TN Study: grazoprevir/elbasvir in genotype 1, 4 or 6 Zeuzem S. Ann Intern Med 2015; 163:1-13

Download ppt "C-EDGE TN Study: grazoprevir/elbasvir in genotype 1, 4 or 6 Zeuzem S. Ann Intern Med 2015; 163:1-13 GZR/EBR 100/50 mg qd N = 316 N = 105  Design W12W24."

Similar presentations

VALENCE SOF + RBV Not randomised Open label* ≥ 18 years Chronic HCV infection Genotype 2 or 3 HCV RNA ≥ 10,000 IU/ml Treatment naïve or prior IFN-based.

VALENCE SOF + RBV Not randomised Open label* ≥ 18 years Chronic HCV infection Genotype 2 or 3 HCV RNA ≥ 10,000 IU/ml Treatment naïve or prior IFN-based.
ATOMIC  Design  Objective –SVR 24 by ITT-analysis, detection of a 30% or 25% difference between two treatment groups, 2-sided significance level of 5%,

ATOMIC  Design  Objective –SVR 24 by ITT-analysis, detection of a 30% or 25% difference between two treatment groups, 2-sided significance level of 5%,
Roth D. EASL 2015, Abs. LP02 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR + EBR (Intensive.

Roth D. EASL 2015, Abs. LP02 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR + EBR (Intensive.
OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind 18-70 years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.

OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.
OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label 18-70 years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.

OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.
OBV/PTV/r Open label 18-70 years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*

OBV/PTV/r Open label years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*
Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a or 1b or other) and IL28B genotype (CC, CT or TT) N = 133 N = 260 W24W48.

Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a or 1b or other) and IL28B genotype (CC, CT or TT) N = 133 N = 260 W24W48.
FUSION  Design  Objectives –SVR ≥ 20% compared with historical control of 25%, 97% power –Difference of SVR > 20% between the 2 groups, 82% power SOF.

FUSION  Design  Objectives –SVR ≥ 20% compared with historical control of 25%, 97% power –Difference of SVR > 20% between the 2 groups, 82% power SOF.
ALLY-2  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, in treatment-naïve genotype 1 treated for 12 weeks DCV + SOF 400 mg QD DCV + SOF.

ALLY-2  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, in treatment-naïve genotype 1 treated for 12 weeks DCV + SOF 400 mg QD DCV + SOF.
FISSION  Design  Objective –Non inferiority of SOF + RBV : SVR 12 (2-sided significance level of 5%, lower margin of the 95% CI for the difference =

FISSION  Design  Objective –Non inferiority of SOF + RBV : SVR 12 (2-sided significance level of 5%, lower margin of the 95% CI for the difference =
AI444040 Study  Design SOF 1W then DCV + SOF 23W DVC + SOF Randomisation* 1 : 1 : 1 Open-label AI444040 Study: DCV + SOF + RBV for genotypes 1, 2 and.

AI Study  Design SOF 1W then DCV + SOF 23W DVC + SOF Randomisation* 1 : 1 : 1 Open-label AI Study: DCV + SOF + RBV for genotypes 1, 2 and.
No HBV or HIV co-infection

No HBV or HIV co-infection
C-EDGE co-infection study: grazoprevir/ elbasvir in HIV coinfection GZR/EBR 100/50 mg qd N = 218  Design W12 W24 C-EDGE co-infection Rockstroh JK. Lancet.

C-EDGE co-infection study: grazoprevir/ elbasvir in HIV coinfection GZR/EBR 100/50 mg qd N = 218  Design W12 W24 C-EDGE co-infection Rockstroh JK. Lancet.
SMV 150 + SOF 400 Open-label OPTIMIST-2 Study: SMV + SOF for genotype 1 and cirrhosis W12  Objective –Superiority of SVR 12 (HCV RNA historical control.

SMV SOF 400 Open-label OPTIMIST-2 Study: SMV + SOF for genotype 1 and cirrhosis W12  Objective –Superiority of SVR 12 (HCV RNA historical control.
SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : 1 18-70 years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥ 10.000.

SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥
UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.

UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.
OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV + placebo Randomisation* Partial blind 18-70 years Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 10,000.

OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV + placebo Randomisation* Partial blind years Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 10,000.
Reddy KR. Lancet Infect Dis. 2015;15:27-35 ATTAIN SMV + TVR placebo + PEG-IFN + RBV TVR + SMV placebo + PEG-IFN + RBV Randomisation* 1 : 1 Double-blind.

Reddy KR. Lancet Infect Dis. 2015;15:27-35 ATTAIN SMV + TVR placebo + PEG-IFN + RBV TVR + SMV placebo + PEG-IFN + RBV Randomisation* 1 : 1 Double-blind.
Placebo + PR W48 Placebo + PR Yes Hezode C. Gut 2015;64:948-56 COMMAND-1 COMMAND-1 Study: daclatasvir + PEG-IFN + RBV for genotype 1 or 4 DCV60 + PEG-IFN.

Placebo + PR W48 Placebo + PR Yes Hezode C. Gut 2015;64: COMMAND-1 COMMAND-1 Study: daclatasvir + PEG-IFN + RBV for genotype 1 or 4 DCV60 + PEG-IFN.
SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.

SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.

Similar presentations

Ads by Google